TINAGL1 and fatty liver disease: Furthermore, TINAGL1 was significantly increased in the livers of patients with metabolic dysfunction associated fatty liver disease (MAFLD), especially with liver fibrosis, as shown by immunohistochemistry (IHC) staining (Figure 1K, Figure S1I and Table S1).